FDA approval of expanded age indication for a tetanus Toxoid, reduced diphtheria Toxoid and Acellular pertussis vaccine

Morbidity and Mortality Weekly Report

Volumn 63, Issue 37, 2011, Pages 1279-1280

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; DIPHTHERIA; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNIZATION; IMMUNOLOGY; MIDDLE AGED; PERTUSSIS; TETANUS; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; DIPHTHERIA; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DRUG APPROVAL; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; MIDDLE AGED; TETANUS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WHOOPING COUGH;

EID: 80054822379     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. CDC. FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR 2009;58:374-5.
2. Food and Drug Administration. Product approval information-licensing action, package insert: tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed (Boostrix, GlaxoSmithKline Biologicals). Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available at http://www.fda.gov/downloads/biologicsbloodvaccines/ucm152842.pdf. Accessed September 9, 2011.
3. CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR 2006;55(No. RR-17).
4. CDC. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-3).
5. CDC. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2008;57(No. RR-4).
6. CDC. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR 2011; 60:13-5.
7. Food and Drug Administration. Proceedings from the Vaccines and Related Biological Products Advisory Committee meeting, convened June 5, 1997, in Bethesda, Maryland. Day one. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 1997. Available at http://www.fda.gov/ohrms/dockets/ac/97/transcpt/3300t1.pdf. Accessed September 9, 2011.
8. Food and Drug Administration. Summary basis for regulatory action. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available at http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm262892.pdf. Accessed September 9, 2011.
9. Schmitt HJ, von Konig CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996;275:37-41.
10. Food and Drug Administration. Product approval information-licensing action, package insert: tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Adacel, Sanofi Pasteur). Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2005. Available at http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm142764.pdf. Accessed September 9, 2011.